[1] Martin Reck, et al. Pembrolizumab versus Chemotherapy forPD-L1–Positive Non–Small-Cell Lung Cancer, N Engl J Med 2016;375:1823-33.[2] Brahmer JR et al. Presented at ASCO 2017,June 2–6, 2017, Chicago, IL. Abstract 9000. [3] Martin Reck et al., Updated Analysis of KEYNOTE-024: PembrolizumabVersus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer WithPD-L1 Tumor Proportion Score of 50% or Greater, Journal of Clinical Oncology, Volume37, Issue 7 537-546[4] Martin Reck et al., KEYNOTE-024 3-Year Survival Update: Pembrolizumabvs Platinum-based Chemotherapy for Advanced Non-Small-Cell Lung Cancer, 2019WCLC, OA14.01[5] Tony S K Mok et al., Pembrolizumab versus chemotherapy forpreviously untreated, PD-L1-expressing, locally advanced or metastaticnon-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled,phase 3 trial, Published Online April 4, 2019 http://dx.doi.org/10.1016/S0140-6736(18)32409-7[6] Wu Y.L et al., KEYNOTE-042 China Study: First-line Pembrolizumabvs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%,Mini-Oral Presentation, 2019 WCLC[7] Ramalingam S.S. et al., Overall Survival with Osimertinib inUntreated, EGFR-Mutated Advanced NSCLC, N Engl J Med 2020;382:41-50.[8] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)Non-Small Cell Lung Cancer Version 6.2020 — June 15, 2020[9] D. Planchard et al., Metastatic non-small cell lung cancer: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up, Annals ofOncology 29 (Supplement 4): iv192–iv237, 2018[10] 2020 CSCO非小细胞肺癌诊疗指南[11] www.merck.com